Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer

被引：559

作者：

Cuzick, Jack ^{[1
]}

Dowsett, Mitch ^{[2
]}

Pineda, Silvia ^{[1
]}

Wale, Christopher ^{[1
]}

Salter, Janine ^{[2
]}

Quinn, Emma ^{[2
]}

Zabaglo, Lila ^{[2
]}

Mallon, Elizabeth ^{[3
]}

Green, Andrew R. ^{[4
,5
]}

Ellis, Ian O. ^{[4
,5
]}

Howell, Anthony ^{[6
,7
]}

Buzdar, Aman U. ^{[8
]}

Forbes, John F. ^{[9
]}

机构：

[1] Queen Mary Univ London, Ctr Canc Prevent, Wolfson Inst Prevent Med, London EC1M 6BQ, England

[2] Royal Marsden Hosp, London SW3 6JJ, England

[3] N Glasgow Univ Hosp, Western Infirm, Glasgow, Lanark, Scotland

[4] Univ Nottingham, Sch Mol Med Sci, Nottingham NG7 2RD, England

[5] City Hosp Nottingham, City Hosp, Nottingham Univ Hosp Natl Hlth Serv Trust, Nottingham, England

[6] Christie Hosp, Manchester Breast Ctr, Manchester, Lancs, England

[7] Break Through Breast Canc Res Unit, Manchester, Lancs, England

[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[9] Univ Newcastle, Sch Med Practice & Populat Hlth, Callaghan, NSW 2308, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 32期

关键词：

EXPRESSION; TAMOXIFEN; WOMEN;

D O I：

10.1200/JCO.2010.31.2835

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose We recently reported that the mRNA-based, 21-gene Genomic Health recurrence score (GHI-RS) provided additional prognostic information regarding distant recurrence beyond that obtained from classical clinicopathologic factors (age, nodal status, tumor size, grade, endocrine treatment) in women with early breast cancer, confirming earlier reports. The aim of this article is to determine how much of this information is contained in standard immunohistochemical (IHC) markers. Patients and Methods The primary cohort comprised 1,125 estrogen receptor-positive (ER-positive) patients from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial who did not receive adjuvant chemotherapy, had the GHI-RS computed, and had adequate tissue for the four IHC measurements: ER, progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), and Ki-67. Distant recurrence was the primary end point, and proportional hazards models were used with sample splitting to control for overfitting. A prognostic model that used classical variables and the four IHC markers (IHC4 score) was created and assessed in a separate cohort of 786 patients. Results All four IHC markers provided independent prognostic information in the presence of classical variables. In sample-splitting analyses, the information in the IHC4 score was found to be similar to that in the GHI-RS, and little additional prognostic value was seen in the combined use of both scores. The prognostic value of the IHC4 score was further validated in the second separate cohort. Conclusion This study suggests that the amount of prognostic information contained in four widely performed IHC assays is similar to that in the GHI-RS. Additional studies are needed to determine the general applicability of the IHC4 score. J Clin Oncol 29: 4273-4278. (C) 2011 by American Society of Clinical Oncology

引用

页码：4273 / 4278

页数：6

共 14 条

[1] High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses [J].

Abd El-Rehim, DM ;

Ball, G ;

Pinder, SE ;

Rakha, E ;

Paish, C ;

Robertson, JFR ;

Macmillan, D ;

Blamey, RW ;

Ellis, IO .

INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (03) :340-350

[2] Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial [J].

Albain, Kathy S. ;

Barlow, William E. ;

Shak, Steven ;

Hortobagyi, Gabriel N. ;

Livingston, Robert B. ;

Yeh, I-Tien ;

Ravdin, Peter ;

Bugarini, Roberto ;

Boehner, Frederick L. ;

Davidson, Nancy E. ;

Sledge, George W. ;

Winer, Eric P. ;

Hudis, Clifford ;

Ingle, James N. ;

Perez, Edith A. ;

Pritchard, Kathleen I. ;

Shepherd, Lois ;

Gralow, Julie R. ;

Yoshizawa, Carl ;

Allred, D. Craig ;

Osborne, C. Kent ;

Hayes, Daniel F. .

LANCET ONCOLOGY, 2010, 11 (01) :55-65

[3] MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups [J].

Aleskandarany, Mohammed A. ;

Rakha, Emad A. ;

Macmillan, R. Douglas ;

Powe, Desmond G. ;

Ellis, Ian O. ;

Green, Andrew R. .

BREAST CANCER RESEARCH AND TREATMENT, 2011, 127 (03) :591-599

[4] Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial [J].

Dowsett, Mitch ;

Allred, Craig ;

Knox, Jill ;

Quinn, Emma ;

Salter, Janine ;

Wale, Chris ;

Cuzick, Jack ;

Houghton, Joan ;

Williams, Norman ;

Mallon, Elizabeth ;

Bishop, Hugh ;

Ellis, Ian ;

Larsimont, Denis ;

Sasano, Hironobu ;

Carder, Pauline ;

Cussac, Antonio Llombart ;

Knox, Fiona ;

Speirs, Valerie ;

Forbes, John ;

Buzdar, Aman .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (07) :1059-1065

[5] International Web-based consultation on priorities for translational breast cancer research [J].

Dowsett, Mitch ;

Goldhirsch, Aron ;

Hayes, Daniel F. ;

Senn, Hans-Joerg ;

Wood, William ;

Viale, Giuseppe .

BREAST CANCER RESEARCH, 2007, 9 (06)

[6] Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study [J].

Dowsett, Mitch ;

Cuzick, Jack ;

Wale, Christopher ;

Forbes, John ;

Mallon, Elizabeth A. ;

Salter, Janine ;

Quinn, Emma ;

Dunbier, Anita ;

Baum, Michael ;

Buzdar, Aman ;

Howell, Anthony ;

Bugarini, Roberto ;

Baehner, Frederick L. ;

Shak, Steven .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) :1829-1834

[7]

Gruber M., 1998, Improving Efficiency by Shrinkage: The James-Stein and Ridge Regression Estimators

[8] American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer [J].

Hammond, M. Elizabeth H. ;

Hayes, Daniel F. ;

Dowsett, Mitch ;

Allred, D. Craig ;

Hagerty, Karen L. ;

Badve, Sunil ;

Fitzgibbons, Patrick L. ;

Francis, Glenn ;

Goldstein, Neil S. ;

Hayes, Malcolm ;

Hicks, David G. ;

Lester, Susan ;

Love, Richard ;

Mangu, Pamela B. ;

McShane, Lisa ;

Miller, Keith ;

Osborne, C. Kent ;

Paik, Soonmyung ;

Perlmutter, Jane ;

Rhodes, Anthony ;

Sasano, Hironobu ;

Schwartz, Jared N. ;

Sweep, Fred C. G. ;

Taube, Sheila ;

Torlakovic, Emina Emilia ;

Valenstein, Paul ;

Viale, Giuseppe ;

Visscher, Daniel ;

Wheeler, Thomas ;

Williams, R. Bruce ;

Wittliff, James L. ;

Wolff, Antonio C. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) :2784-2795

[9] Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial [J].

Mauriac, L. ;

Keshaviah, A. ;

Debled, M. ;

Mouridsen, H. ;

Forbes, J. F. ;

Thuerlimann, B. ;

Paridaens, R. ;

Monnier, A. ;

Lang, I. ;

Wardley, A. ;

Nogaret, J.-M. ;

Gelber, R. D. ;

Castiglione-Gertsch, M. ;

Price, K. N. ;

Coates, A. S. ;

Smith, I. ;

Viale, G. ;

Rabaglio, M. ;

Zabaznyi, N. ;

Goldhirsch, A. .

ANNALS OF ONCOLOGY, 2007, 18 (05) :859-867

[10] Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer [J].

Paik, Soonmyung ;

Tang, Gong ;

Shak, Steven ;

Kim, Chungyeul ;

Baker, Joffre ;

Kim, Wanseop ;

Cronin, Maureen ;

Baehner, Frederick L. ;

Watson, Drew ;

Bryant, John ;

Costantino, Joseph P. ;

Geyer, Charles E., Jr. ;

Wickerham, D. Lawrence ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (23) :3726-3734

← 1 2 →